Acute heart failure data for Corthera's relaxin data "probably too good to be true"
This article was originally published in Scrip
The US biopharmaceutical company Corthera (formerly BAS Medical) is set to take its lead product, a recombinant version of the human hormone relaxin, into Phase III by the end of this year on the back of highly promising Phase IIb data in acute heart failure (AHF).
You may also be interested in...
The US FDA has given the go-ahead for marketing of ViiV healthcare’s novel HIV drug just as the EMA removes the accelerated assessment status from its application there.
Executives On The Move: BioXcel Therapeutics Picks A Development Officer, A Finance Hire At RenovaCare And CANbridge Taps Takeda Talent
Immuno-oncology and neuroscience firm BioXcel Therapeutics picks a chief development officer, and stem-cell therapy company RenovaCare hires a CFO. Plus, CANbridge Life Sciences, developer of specialty health products, adds Takeda Pharma rare disease lead as global head, business development.
Topline Phase II data for the antibody-drug conjugate tisotumab vedotin put it on a swift path towards approval in cervical cancer.